500 related articles for article (PubMed ID: 32003247)
41. How to Understand Personalized Medicine in Atopic Dermatitis Nowadays?
Mesjasz A; Kołkowski K; Wollenberg A; Trzeciak M
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108720
[TBL] [Abstract][Full Text] [Related]
42. New and Emerging Biologics for Atopic Dermatitis.
Baghoomian W; Na C; Simpson EL
Am J Clin Dermatol; 2020 Aug; 21(4):457-465. PubMed ID: 32323259
[TBL] [Abstract][Full Text] [Related]
43. Monoclonal antibodies for moderate-to-severe atopic dermatitis: a look at phase III and beyond.
David E; Hawkins K; Shokrian N; Del Duca E; Guttman-Yassky E
Expert Opin Biol Ther; 2024 Jun; 24(6):471-489. PubMed ID: 38888099
[TBL] [Abstract][Full Text] [Related]
44. Mapping atopic dermatitis and anti-IL-22 response signatures to type 2-low severe neutrophilic asthma.
Badi YE; Pavel AB; Pavlidis S; Riley JH; Bates S; Kermani NZ; Knowles R; Kolmert J; Wheelock CE; Worsley S; Uddin M; Alving K; Bakke PS; Behndig A; Caruso M; Chanez P; Fleming LJ; Fowler SJ; Frey U; Howarth P; Horváth I; Krug N; Maitland-van der Zee AH; Montuschi P; Roberts G; Sanak M; Shaw DE; Singer F; Sterk PJ; Djukanovic R; Dahlen SE; Guo YK; Chung KF; Guttman-Yassky E; Adcock IM;
J Allergy Clin Immunol; 2022 Jan; 149(1):89-101. PubMed ID: 33891981
[TBL] [Abstract][Full Text] [Related]
45. Biologic Therapy for Atopic Dermatitis: Moving Beyond the Practice Parameter and Guidelines.
Boguniewicz M
J Allergy Clin Immunol Pract; 2017; 5(6):1477-1487. PubMed ID: 29122151
[TBL] [Abstract][Full Text] [Related]
46. Dupilumab for treatment of atopic dermatitis.
Seegräber M; Srour J; Walter A; Knop M; Wollenberg A
Expert Rev Clin Pharmacol; 2018 May; 11(5):467-474. PubMed ID: 29557246
[TBL] [Abstract][Full Text] [Related]
47. Increased IL-26 Expression Promotes T Helper Type 17- and T Helper Type 2-Associated Cytokine Production by Keratinocytes in Atopic Dermatitis.
Kamijo H; Miyagaki T; Hayashi Y; Akatsuka T; Watanabe-Otobe S; Oka T; Shishido-Takahashi N; Suga H; Sugaya M; Sato S
J Invest Dermatol; 2020 Mar; 140(3):636-644.e2. PubMed ID: 31465744
[TBL] [Abstract][Full Text] [Related]
48. Target-oriented therapy: Emerging drugs for atopic dermatitis.
Lauffer F; Ring J
Expert Opin Emerg Drugs; 2016; 21(1):81-9. PubMed ID: 26808004
[TBL] [Abstract][Full Text] [Related]
49. From Emollients to Biologicals: Targeting Atopic Dermatitis.
Salvati L; Cosmi L; Annunziato F
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638722
[TBL] [Abstract][Full Text] [Related]
50. Atopic dermatitis: a review of evolving targeted therapies.
Kalamaha K; Reis E; Newton S; Roche C; Julson J; Fernandes H; Rodrigues J
Expert Rev Clin Immunol; 2019 Mar; 15(3):275-288. PubMed ID: 30577713
[TBL] [Abstract][Full Text] [Related]
51. So close, and yet so far away: The dichotomy of the specific immune response and inflammation in psoriasis and atopic dermatitis.
Schäbitz A; Eyerich K; Garzorz-Stark N
J Intern Med; 2021 Jul; 290(1):27-39. PubMed ID: 33428274
[TBL] [Abstract][Full Text] [Related]
52. Drug evaluation review: dupilumab in atopic dermatitis.
Hamilton JD; Ungar B; Guttman-Yassky E
Immunotherapy; 2015; 7(10):1043-58. PubMed ID: 26598956
[TBL] [Abstract][Full Text] [Related]
53. Immunotherapy in atopic dermatitis.
Li W; Man XY
Immunotherapy; 2022 Oct; 14(14):1149-1164. PubMed ID: 36046941
[TBL] [Abstract][Full Text] [Related]
54. Emerging systemic therapies for atopic dermatitis: biologics.
Nusbaum KB; Nguyen CM; Fleischer AB
J Dermatolog Treat; 2022 May; 33(3):1269-1273. PubMed ID: 33045848
[TBL] [Abstract][Full Text] [Related]
55. Dupilumab in the treatment of moderate-to-severe atopic dermatitis.
Kraft M; Worm M
Expert Rev Clin Immunol; 2017 Apr; 13(4):301-310. PubMed ID: 28165826
[TBL] [Abstract][Full Text] [Related]
56. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
[TBL] [Abstract][Full Text] [Related]
57. [Status quo and prospects for systemic therapy of atopic dermatitis. Biologics ante portas].
Biedermann T; Werfel T
Hautarzt; 2015 Feb; 66(2):108-13. PubMed ID: 25645542
[TBL] [Abstract][Full Text] [Related]
58. Towards personalized treatment in atopic dermatitis.
van der Schaft J; Thijs JL; Garritsen FM; Balak D; de Bruin-Weller MS
Expert Opin Biol Ther; 2019 May; 19(5):469-476. PubMed ID: 30768375
[TBL] [Abstract][Full Text] [Related]
59. Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders.
Balato A; Scala E; Balato N; Caiazzo G; Di Caprio R; Monfrecola G; Raimondo A; Lembo S; Ayala F
Expert Opin Biol Ther; 2017 Nov; 17(11):1363-1374. PubMed ID: 28791896
[TBL] [Abstract][Full Text] [Related]
60. Systemic therapies in atopic dermatitis: The pipeline.
Renert-Yuval Y; Guttman-Yassky E
Clin Dermatol; 2017; 35(4):387-397. PubMed ID: 28709570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
